Quantitative digital pathology, run by people with their own pipeline to defend

Three phases, three evidence standards

The analysis techniques overlap. What changes is how tightly the process is controlled and how much of it has to be reconstructable years later.

Where we have depth

• Gynaecological oncology

  High-grade serous ovarian, endometrial and cervical tissue. Folate receptor alpha expression scoring, Ki67 proliferation index, tumour–stroma segmentation, peritoneal implant morphometry, and carrier biodistribution readouts in orthotopic models.

• Immuno-oncology

  Quantification of lymphocyte and inflammatory populations within tumour tissue, co-localisation of activation markers, immune infiltration at defined distances inside and outside the tumour border, and spatial relationships between interacting cell types across the microenvironment.

• Fibrosis & steatohepatitis

  Collagen proportionate area, fibrosis staging support, steatosis quantification, ballooning and inflammatory foci counting across liver, lung, kidney and cardiac tissue.

• Dermatology

  Epidermal thickness, drug target expression through the skin layers, inflammatory cell infiltrate, and cell-by-cell drug response effects in histology and IHC material.

• Central nervous system

  Quantification of brain structures and cell types, neurotransmitter distribution, infarct region measurement, plaque and deposit burden, and glial activation.

• Cardiovascular

  Plaque composition and burden in atherosclerosis models, vessel wall morphometry after injury, fibrotic and infarct area in cardiac tissue.

• Metabolic disease

  Islet identification as a region of interest in pancreatic sections, with quantification of insulin-secreting beta cells and glucagon-secreting alpha cells, cell numbers and expression levels.